VBL Therapeutics Announces Closing of Initial Public Offering
October 06, 2014 19:16 ET
|
VBL Therapeutics
TEL AVIV, Israel, Oct. 6, 2014 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory...
VBL Therapeutics Announces Pricing of Initial Public Offering
September 30, 2014 22:38 ET
|
VBL Therapeutics
TEL AVIV, Israel, Sept. 30, 2014 (GLOBE NEWSWIRE) -- VBL Therapeutics, a clinical-stage biotechnology company committed to the discovery, development and commercialization of first-in-class treatments...
VBL Therapeutics Announces Termination of Underwriting Agreement for Public Offering
August 08, 2014 09:28 ET
|
VBL Therapeutics
TEL AVIV, Israel, Aug. 8, 2014 (GLOBE NEWSWIRE) -- VBL Therapeutics today announced that the underwriting agreement for its initial public offering has been terminated by the Company's underwriters,...
VBL Therapeutics Announces Pricing of Initial Public Offering
July 30, 2014 23:27 ET
|
VBL Therapeutics
TEL AVIV, Israel, July 30, 2014 (GLOBE NEWSWIRE) -- VBL Therapeutics, a clinical-stage biotechnology company committed to the discovery, development and commercialization of first-in-class treatments...
VBL Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Studies of VB-201 in Psoriasis and Ulcerative Colitis
June 20, 2014 07:01 ET
|
VBL Therapeutics
TEL AVIV, Israel, June 20, 2014 (GLOBE NEWSWIRE) -- VBL Therapeutics, a clinical-stage biotechnology company committed to the development of first-in-class treatments for immune-inflammatory diseases...